Eosinophils in wound healing and epithelial remodeling: Is coagulation a missing link?
Eosinophils
allergy
cancer
coagulation
fibrin
fibrinogen
heart disease
plasminogen
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
14
11
2019
revised:
31
01
2020
accepted:
14
02
2020
pubmed:
15
3
2020
medline:
2
12
2020
entrez:
15
3
2020
Statut:
ppublish
Résumé
Eosinophils are often cited as playing roles in wound healing and epithelial remodeling; however, the exact triggers and mechanisms of such activity remain poorly understood. Eosinophils show the remarkable capacity to partner with coagulation, which is a highly conserved biologic system evolved to protect an organism from injury by promoting hemostasis and tissue repair. Eosinophils contribute directly by producing key factors in coagulation (tissue factor, thrombin) and fibrinolysis (plasminogen). Moreover, they have been shown to interact with other players in these cascades, such as fibrinogen and the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system, which further promotes coagulation and fibrinolysis. Although primarily thought of in the contexts of blood clotting and vascular repair, coagulation and fibrinolytic systems play key roles within tissue, in particular during epithelial injury and remodeling. Chronic inflammation and remodeling frequently associate with pro-thrombotic and pro-coagulation state. There is a striking association between eosinophils and dysregulated coagulation in animal models and human disease. This review will examine the mechanistic links between eosinophils and the coagulation system in the context of epithelial injury and repair, as well as evidence for this interaction in heart disease, type 2 inflammatory diseases, and cancer. Collectively, multiple emerging studies summarized in this review elucidate an overlooked, but potentially fundamental, biologic mechanism to engage eosinophils in processes of epithelial injury and repair.
Identifiants
pubmed: 32170876
doi: 10.1002/JLB.3MR0120-390R
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-103Subventions
Organisme : NIH HHS
ID : R21AI115055
Pays : United States
Organisme : NIH HHS
ID : R01AI127783
Pays : United States
Informations de copyright
©2020 Society for Leukocyte Biology.
Références
Gleich GJ. The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol. 1990;85:422-436.
Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40:563-575.
Chusid MJ. Eosinophils: friends or foes? J Allergy Clin Immunol Pract. 2018;6:1439-1444.
Takeda K, Shiraishi Y, Ashino S, et al. Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge. J Allergy Clin Immunol. 2015;135:451-460.
Abdala-Valencia H, Coden ME, Chiarella SE, et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol. 2018;104:95-108.
Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003;31:S213-20.
de Boer JD, Majoor CJ, van ’t Veer C, Bel EH, van der Poll T. Asthma and coagulation. Blood. 2012;119:3236-3244.
Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas. 2004;47:305-314.
Majoor CJ, van de Pol MA, Kamphuisen PW, et al. Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respir Res. 2014;15:14.
Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J Allergy Clin Immunol. 2017;139:1752-1761.
Vazquez JJ, Fernandez Pavon A, Arnalich F, et al. Coagulation abnormalities in patients with eosinophilia. Postgrad Med J. 1987;63:943-945.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93:327-358.
Gebbink MF, Bouma B, Maas C, Bouma BN. Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors). FEBS Lett. 2009;583:2691-2699.
Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood. 2009;114:4886-4896.
Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost. 2006;32:11-23.
Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311-2315.
Halvorsen H, Olsen JO, Osterud B. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J Leukoc Biol. 1993;54:275-282.
Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood. 2007;109:995-1002.
Cugno M, Marzano AV, Lorini M, Carbonelli V, Tedeschi A. Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis. PLoS One. 2014;9:e111862.
Sovershaev MA, Lind KF, Devold H, et al. No evidence for the presence of tissue factor in high-purity preparations of immunologically isolated eosinophils. J Thromb Haemost. 2008;6:1742-1749.
Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol. 2009;148:170-174.
Shimizu S, Ogawa T, Takezawa K, Tojima I, Kouzaki H, Shimizu T. Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp. Am J Rhinol Allergy. 2015;29:235-242.
Kim DY, Cho SH, Takabayashi T, Schleimer RP. Chronic rhinosinusitis and the coagulation system. Allergy Asthma Immunol Res. 2015;7:421-430.
Nesheim M. Thrombin and fibrinolysis. Chest. 2003;124:33S-9S.
Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006;32(Suppl 1):3-15.
Uderhardt S, Ackermann JA, Fillep T, et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J Exp Med. 2017;214:2121-2138.
Feistritzer C, Mosheimer BA, Kaneider NC, Riewald M, Patsch JR, Wiedermann CJ. Thrombin affects eosinophil migration via protease-activated receptor-1. Int Arch Allergy Immunol. 2004;135:12-16.
Shimizu S, Tojima I, Takezawa K, Matsumoto K, Kouzaki H, Shimizu T. Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors. Am J Rhinol Allergy. 2017;31:13-18.
Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest. 1993;91:1721-1730.
Pulanic D, Rudan I. The past decade: fibrinogen. Coll Antropol. 2005;29:341-349.
Drury DR, McMaster PD. The liver as the source of fibrinogen. J Exp Med. 1929;50:569-578.
Pieters M, Wolberg AS. Fibrinogen and fibrin: an illustrated review. Res Pract Thromb Haemost. 2019;3:161-172.
Lawrence SO, Simpson-Haidaris PJ. Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflammation. Thromb Haemost. 2004;92:234-243.
Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood. 1997;89:873-882.
Valencia Abdala, H Loffredo, F L, Misharin AV, Berdnikovs S. Phenotypic plasticity and targeting of Siglec-F(high) CD11c(low) eosinophils to the airway in a murine model of asthma. Allergy. 2016;71:267-271.
Barthel SR, Jarjour NN, Mosher DF, Johansson MW. Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol. 2006;35:378-386.
Coden ME, Loffredo LF, Walker MT, et al. Fibrinogen is a specific trigger for cytolytic eosinophil degranulation. J Immunol. 2020;204:438-448.
Lippi G, Montagnana M, Salvagno GL, Franchini M, Targher G, Guidi GC. Eosinophilia and first-line coagulation testing. J Thromb Thrombolysis. 2009;28:90-93.
Millien VO, Lu W, Shaw J, et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science. 2013;341:792-796.
Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science. 1980;208:1036-1037.
Moroz LA. Mini-plasminogen: a mechanism for leukocyte modulation of plasminogen activation by urokinase. Blood. 1981;58:97-104.
Barnhart MI, Riddle JM. Cellular localization of profibrinolysin (plasminogen). Blood. 1963;21:306-321.
Prokopowicz J, Stormorken H. Fibrinolytic activity of leucocytes in smears of bone marrow and peripheral blood. Scand J Haematol. 1968;5:129-137.
Ferland C, Guilbert M, Davoine F, Flamand N, Chakir J, Laviolette M. Eotaxin promotes eosinophil transmigration via the activation of the plasminogen-plasmin system. J Leukoc Biol. 2001;69:772-778.
Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest. 1991;87:962-970.
Schuliga M. The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm. 2015;2015:437695.
Plesner T, Ralfkiaer E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 1994;102:835-841.
Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15:398-408.
Bolton SJ, McNulty CA, Thomas RJ, Hewitt CR, Wardlaw AJ. Expression of and functional responses to protease-activated receptors on human eosinophils. J Leukoc Biol. 2003;74:60-68.
Majumdar M, Tarui T, Shi B, Akakura N, Ruf W, Takada Y. Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1). J Biol Chem. 2004;279:37528-37534.
Doan TC, Jeong BM, Coden ME, et al. Matrix protein tenascin-C expands and reversibly blocks maturation of murine eosinophil progenitors. J Allergy Clin Immunol. 2018;142:695-698 e4.
Yokosaki Y, Matsuura N, Higashiyama S, et al. Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. J Biol Chem. 1998;273:11423-11428.
Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem. 1996;271:28485-28491.
Clark RA. Fibrin is a many splendored thing. J Invest Dermatol. 2003;121:xxi-xxii.
Astrup T. Blood coagulation and fibrinolysis in tissue culture and tissue repair. Biochem Pharmacol. 1968(Suppl):241-257.
Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res. 2012;49:35-43.
Ellis S, Lin EJ, Tartar D. Immunology of wound healing. Curr Dermatol Rep. 2018;7:350-358.
Gieseck RL, 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62-76.
Berek C. Eosinophils can more than kill. J Exp Med. 2018;215:1967-1969.
Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112:1029-1036.
Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol. 2005;116:796-804.
Guadiz G, Sporn LA, Goss RA, Lawrence SO, Marder VJ, Simpson-Haidaris PJ. Polarized secretion of fibrinogen by lung epithelial cells. Am J Respir Cell Mol Biol. 1997;17:60-69.
Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound healing: a cellular perspective. Physiol Rev. 2019;99:665-706.
Erjefalt JS, Greiff L, Andersson M, et al. Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways. Am J Respir Crit Care Med. 1999;160:304-312.
Neves JS, Perez SA, Spencer LA, et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci U S A. 2008;105:18478-18483.
Erjefalt JS, Persson CG. New aspects of degranulation and fates of airway mucosal eosinophils. Am J Respir Crit Care Med. 2000;161:2074-2085.
Cheng JF, Ott NL, Peterson EA, et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol. 1997;99:683-692.
Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17:746-760.
Pegorier S, Wagner LA, Gleich GJ, Pretolani M. Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. J Immunol. 2006;177:4861-4869.
Zagai U, Dadfar E, Lundahl J, Venge P, Skold CM. Eosinophil cationic protein stimulates TGF-beta1 release by human lung fibroblasts in vitro. Inflammation. 2007;30:153-160.
Galdiero MR, Varricchi G, Seaf M, Marone G, Levi-Schaffer F, Marone G. Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer. Front Med (Lausanne). 2017;4:103.
Brooks AM, Bates ME, Vrtis RF, Jarjour NN, Bertics PJ, Sedgwick JB. Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma. Am J Respir Cell Mol Biol. 2006;35:503-511.
Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol. 2000;157:177-187.
Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11:23-36.
Sitrin RG, Todd RF, 3rd, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest. 1996;97:1942-1951.
May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998;188:1029-1037.
Reuning U, Magdolen V, Hapke S, Schmitt M. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem. 2003;384:1119-1131.
Goh YP, Henderson NC, Heredia JE, et al. Eosinophils secrete IL-4 to facilitate liver regeneration. Proc Natl Acad Sci U S A. 2013;110:9914-9919.
Todd R, Donoff BR, Chiang T, et al. The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds. Am J Pathol. 1991;138:1307-1313.
Elovic A, Wong DT, Weller PF, Matossian K, Galli SJ. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol. 1994;93:864-869.
Wong DT, Elovic A, Matossian K, et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood. 1991;78:2702-2707.
Levi-Schaffer F, Garbuzenko E, Rubin A, et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci U S A. 1999;96:9660-9665.
Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol. 1997;17:519-528.
Ohno I, Ohtani H, Nitta Y, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol. 1997;16:212-219.
Kariyawasam HH, Robinson DS. The role of eosinophils in airway tissue remodelling in asthma. Curr Opin Immunol. 2007;19:681-686.
Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38:S26-34.
van der Poll T, Levi M, Buller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med. 1991;174:729-732.
van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994;179:1253-1259.
Sower LE, Froelich CJ, Carney DH, Fenton JW, 2nd, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol. 1995;155:895-901.
de Jonge E, Friederich PW, Vlasuk GP, et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol. 2003;10:495-497.
Jiang P, Wang DZ, Ren YL, Cai JP, Chen BX. Significance of eosinophil accumulation in the thrombus and decrease in peripheral blood in patients with acute coronary syndrome. Coron Artery Dis. 2015;26:101-106.
Riegger J, Byrne RA, Joner M, et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J. 2016;37:1538-1549.
Seguela PE, Iriart X, Acar P, Montaudon M, Roudaut R, Thambo JB. Eosinophilic cardiac disease: molecular, clinical and imaging aspects. Arch Cardiovasc Dis. 2015;108:258-268.
Sharma SK, Kumar S, Seth T, Mishra P, Mahapatra M. Eosinophilia: rare cause of arterial thrombosis and cardioembolic stroke in childhood. World J Cardiol. 2012;4:128-129.
Guo LB, Liu S, Zhang F, Mao GS, Sun LZ, Liu Y. The role of eosinophils in stroke: a pilot study. Eur Rev Med Pharmacol Sci. 2015;19:3643-3648.
Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000;86:110-113.
Ogbogu PU, Rosing DR. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:457-475.
Passerini Gambacorti C, Cortellaro M, Cofrancesco E, et al. Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. Haemostasis. 1989;19:32-37.
Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006;107:558-565.
Venge P, Dahl R, Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res. 1979;14:641-649.
Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. J Exp Med. 1990;172:1271-1274.
Gabazza EC, Osamu T, Yamakami T, et al. Correlation between clotting and collagen metabolism markers in rheumatoid arthritis. Thromb Haemost. 1994;71:199-202.
Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn's disease. Blood Coagul Fibrinolysis. 1992;3:773-778.
Lambrecht BN, Hammad H. Asthma and coagulation. N Engl J Med. 2013;369:1964-1966.
Brims FJ, Chauhan AJ, Higgins B, Shute JK. Up-regulation of the extrinsic coagulation pathway in acute asthma-a case study. J Asthma. 2010;47:695-698.
Carmassi F, de Negri F, Morale M, Song KY, Chung SI. Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis. Semin Thromb Hemost. 1996;22:489-496.
Levi M, Schultz MJ, Rijneveld AW, van der Poll T. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med. 2003;31:S238-42.
Hara K, Hasegawa T, Ooi H, et al. Inhibitory role of eosinophils on cell surface plasmin generation by bronchial epithelial cells: inhibitory effects of transforming growth factor beta. Lung. 2001;179:9-20.
Vignola AM, Kips J, Bousquet J. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol. 2000;105:1041-1053.
Wagers SS, Norton RJ, Rinaldi LM, Bates JH, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest. 2004;114:104-111.
Brims FJ, Chauhan AJ, Higgins B, Shute JK. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Thorax. 2009;64:1037-1043.
Wu D, Wei Y, Bleier BS. Emerging role of proteases in the pathogenesis of chronic rhinosinusitis with nasal polyps. Front Cell Infect Microbiol. 2017;7:538.
Azouz NP, Ynga-Durand MA, Caldwell JM, et al. The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses. Sci Transl Med. 2018;10.
Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:1407-1414, quiz 1415.
Kelly MT, Martin RR, White A. Mediators of histamine release from human platelets, lymphocytes, and granulocytes. J Clin Invest. 1971;50:1044-1049.
Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest. 1986;78:1701-1706.
Song WL, Stubbe J, Ricciotti E, et al. Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans. J Clin Invest. 2012;122:1459-1468.
Moritani C, Ishioka S, Haruta Y, Kambe M, Yamakido M. Activation of platelets in bronchial asthma. Chest. 1998;113:452-458.
Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014;123:2759-2767.
Kowal K, Pampuch A, Kowal-Bielecka O, DuBuske LM, Bodzenta-Lukaszyk A. Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin Exp Allergy. 2006;36:426-432.
Kornerup KN, Page CP. The role of platelets in the pathophysiology of asthma. Platelets. 2007;18:319-328.
Pitchford SC, Yano H, Lever R, et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol. 2003;112:109-118.
Pitchford SC, Momi S, Giannini S, et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood. 2005;105:2074-2081.
Schuliga M, Westall G, Xia Y, Stewart AG. The plasminogen activation system: new targets in lung inflammation and remodeling. Curr Opin Pharmacol. 2013;13:386-393.
Reichman H, Itan M, Rozenberg P, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7:388-400.
Munitz A, Hogan SP. Alarming eosinophils to combat tumors. Nat Immunol. 2019;20:250-252.
Rigoni A, Colombo MP, Pucillo C. Mast cells, basophils and eosinophils: from allergy to cancer. Semin Immunol. 2018;35:29-34.
Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68:823-833.
Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223-233.
Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013;33.
Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11:2531-2539.
Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int J Cancer. 2008;122:1592-1597.
Schardt FW, Schmausser B, Bachmann E. Monoclonal antibodies for immunodectection of fibrin deposits on cancer cells. Histol Histopathol. 2013;28:993-998.
Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol. 2010;19:e33-46.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
Reeves BN, Key NS. Acquired hemophilia in malignancy. Thromb Res. 2012;129(Suppl 1):S66-8.
Saito M, Ogasawara R, Izumiyama K, et al. Acquired hemophilia A in solid cancer: two case reports and review of the literature. World J Clin Cases. 2018;6:781-785.
Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer. Oncoimmunology. 2018;7:e1393134.
Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavourable. Curr Med Chem. 2016;23:650-666.
Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol. 1997;17:70-77.
Efraim NissimBen, H A, Eliashar R, Levi-Schaffer F. Hypoxia modulates human eosinophil function. Clin Mol Allergy. 2010;8:10.
Puxeddu I, Berkman N, Ribatti D, et al. Osteopontin is expressed and functional in human eosinophils. Allergy. 2010;65:168-174.
Prizment AE, Vierkant RA, Smyrk TC, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study. Mod Pathol. 2016;29:516-527.
Ownby HE, Roi LD, Isenberg RR, Brennan MJ. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer. 1983;52:126-130.
Cuschieri A, Talbot IC, Weeden S, Party MRCUGCW. Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer. 2002;86:674-679.
Kaufmann R, Rahn S, Pollrich K, et al. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol. 2007;211:699-707.